Patents by Inventor Pavandeep Aujla

Pavandeep Aujla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7888344
    Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: February 15, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Aujla, Mark James Batchelor, Daniel Christopher Brookings, George Martin Buckley, Karen Viviane Lucile Crepy, Claire Louise Kulisa, James Petrie Turner
  • Patent number: 7557130
    Abstract: Compounds of formula (1) are described: in which X is an —O— or —S— atom or —N(R2)— group and R1 is a group Ar1L2Ar2Alk- in which Ar1 is an optionally substituted aromatic or heteroaromatic group, L2 is a covalent bond or a linker atom or group, Ar2 is an optionally substituted bicyclic heteroarylene group and Alk is a chain —CH2—CH(R)—, —CH?C(R)—, OR—CH(CH2R)— in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof. The compounds are selective inhibitors of alpha 4 integrins such as ?4?1 and are of use in modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: July 7, 2009
    Assignee: UCB Pharma, S.A.
    Inventors: Pavandeep Aujla, Timothy John Norman, John Robert Porter, Stuart Bailey, Stephen Brand
  • Publication number: 20080306060
    Abstract: A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: April 25, 2006
    Publication date: December 11, 2008
    Applicant: UCB PHARMA S.A.
    Inventors: Rikki Peter Alexander, Pavandeep Aujla, Mark James Batchelor, Daniel Christopher Brookings, George Martin Buckley, Karen Viviane Lucile Crepy, Claire Louise Kulisa, James Petrie Turner
  • Publication number: 20040209913
    Abstract: Compounds of formula (1) are described: in which X is an —O— or —S— atom or —N(R2)— group and R1 is a group Ar1L2Ar2Alk- in which Ar1 is an optionally substituted aromatic or heteroaromatic group, L2 is a covalent bond or a linker atom or group, Ar2 is an optionally substituted bicyclic heteroarylene group and Alk is a chain —CH2—CH(R)—, —CH═C(R)—, OR—CH(CH2R)— or which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof. The compounds are selective inhibitors of alpha 4 integrins such as &agr;4&bgr;1 and are of use in modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role.
    Type: Application
    Filed: April 29, 2004
    Publication date: October 21, 2004
    Inventors: Pavandeep Aujla, John Robert Porter, Stuart Bailey, Stephen Brand